Hajime Sasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hajime Sasaki has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Tatsu Tanabe
Department of Kidney Transplant Surgery Sapporo City General Hospital Sapporo Japan
7 shared publicationsHiroshi Tanaka
6 shared publicationsHiroshi Harada
5 shared publications- Kiyohiko Hotta
Department of Renal and Genitourinary Surgery, Faculty of Medicine Hokkaido University Sapporo Japan
5 shared publications Daiji Takamoto
4 shared publications- Takahiro Tsuji
Department of Pathology Sapporo City General Hospital Sapporo Japan
4 shared publications
Latest Publications
- 24 August 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (8)
Short Pretransplant Dialysis Periods are Clinically Acceptable Without Compromising Kidney Transplant Outcomes: A Japanese Multicenter Study
Objectives: Preemptive kidney transplantation (PEKT) is known to have better outcomes than kidney transplantation (KT) after dialysis therapy. However, the effect of pretransplant dialysis duration (PTDD) on KT outcomes under good hemodialysis control remains unclear. We investigated the association between PTDD and KT outcomes in a Japanese cohort with favorable dialysis management. Methods: Among three institutions, 805 patients who underwent a living donor KT between 2001 and 2021 were enrolled in this study. Those who underwent more than one KT, multiple organ transplantations in addition to KT, or transplantations at < 20 years of age were excluded. Calcineurin inhibitors, mycophenolate mofetil, and steroids were the primary maintenance immunosuppressors. Results: The allograft survival rates of the non‐PEKT group were significantly lower than those of the PEKT group (hazard ratio [HR] 1.67, 95% confidence interval [CI] 1.04–2.70). Univariate analysis showed that ≥ 2 years of PTDD demonstrated the highest HR for allograft loss when PTDD was separated by year (95% CI 1.11–2.55). Multivariate analysis showed that ≥ 2 years of PTDD (HR 2.61 [95% CI 1.58–4.38]), being a male recipient (HR 2.35 [95% CI 1.30–4.53]), and having diabetic nephropathy (HR 2.94 [95% CI 1.71–4.98]) were suggested to be risk factors for allograft loss. Additionally, < 2 years of PTDD resulted in significantly higher allograft survival rates; the 10‐year allograft survival rates of recipients with ≥ 2 years and < 2 years of PTDD were 82.0% and 91.8%, respectively. Conclusions: Allograft survival remained unaffected when KT is performed after a short‐term dialysis introduction.
- 24 August 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (8)
Short Pretransplant Dialysis Periods are Clinically Acceptable Without Compromising Kidney Transplant Outcomes: A Japanese Multicenter Study
Objectives: Preemptive kidney transplantation (PEKT) is known to have better outcomes than kidney transplantation (KT) after dialysis therapy. However, the effect of pretransplant dialysis duration (PTDD) on KT outcomes under good hemodialysis control remains unclear. We investigated the association between PTDD and KT outcomes in a Japanese cohort with favorable dialysis management. Methods: Among three institutions, 805 patients who underwent a living donor KT between 2001 and 2021 were enrolled in this study. Those who underwent more than one KT, multiple organ transplantations in addition to KT, or transplantations at < 20 years of age were excluded. Calcineurin inhibitors, mycophenolate mofetil, and steroids were the primary maintenance immunosuppressors. Results: The allograft survival rates of the non‐PEKT group were significantly lower than those of the PEKT group (hazard ratio [HR] 1.67, 95% confidence interval [CI] 1.04–2.70). Univariate analysis showed that ≥ 2 years of PTDD demonstrated the highest HR for allograft loss when PTDD was separated by year (95% CI 1.11–2.55). Multivariate analysis showed that ≥ 2 years of PTDD (HR 2.61 [95% CI 1.58–4.38]), being a male recipient (HR 2.35 [95% CI 1.30–4.53]), and having diabetic nephropathy (HR 2.94 [95% CI 1.71–4.98]) were suggested to be risk factors for allograft loss. Additionally, < 2 years of PTDD resulted in significantly higher allograft survival rates; the 10‐year allograft survival rates of recipients with ≥ 2 years and < 2 years of PTDD were 82.0% and 91.8%, respectively. Conclusions: Allograft survival remained unaffected when KT is performed after a short‐term dialysis introduction.
- 28 July 2026
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
Apparent Elevation of Whole-Blood Tacrolimus Concentrations Following High-Dose Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients
Background: The effect of massive immunoglobulin G (IgG) elevation on highly protein-bound tacrolimus (TAC) after high-dose intravenous immunoglobulin (IVIG) therapy remains uncharacterized. Misinterpreting IVIG-induced whole-blood TAC elevation as increased unbound fraction risks underdosing and rejection in donor-specific antibody-positive kidney transplant recipients. The aim of this study was to investigate the interaction between IVIG-induced IgG elevation and TAC during preoperative desensitization. Methods: This retrospective study compared TAC trough levels (C 0 ), area under the concentration–time curve from 0 to 24 hours (AUC 0–24 ), TAC C 0 /dose (C 0 /D), TAC AUC 0–24 /dose (AUC 0–24 /D), and serum IgG levels predesensitization and postdesensitization among 3 groups: IVIG [high-dose IVIG plus plasmapheresis (PP), n = 12], PP only (n = 7), and control (n = 68). Results: Following IVIG, median whole blood TAC C 0 rose from 6.5 to 9.3 ng/mL and AUC 0–24 from 238.2 to 325.8 ng·hours/mL. Accordingly, serum IgG levels increased from 968 (898–1396) to 2647 (2349–2927) mg/dL. A linear mixed model confirmed that an increase in serum IgG levels was independently associated with an elevated TAC AUC 0–24 /D. This apparent TAC AUC 0–24 /D increase peaked at 1.3-fold and persisted for 2 weeks; however, no clinical evidence of TAC toxicity (eg, hyperkalemia) was observed, suggesting an unlikely rise in the unbound concentration. Conclusions: IVIG induced an apparent elevation in whole-blood TAC concentrations, mediated by elevated serum IgG levels. Because this elevation theoretically may not reflect an increase in the unbound fraction, empirical dose reductions based solely on whole-blood levels risk compromising immunosuppression. A vigilant therapeutic drug monitoring strategy is essential to account for the protein-binding interaction and potentially optimize immunosuppression in high-risk patients.
- 28 July 2026
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
Apparent Elevation of Whole-Blood Tacrolimus Concentrations Following High-Dose Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients
Background: The effect of massive immunoglobulin G (IgG) elevation on highly protein-bound tacrolimus (TAC) after high-dose intravenous immunoglobulin (IVIG) therapy remains uncharacterized. Misinterpreting IVIG-induced whole-blood TAC elevation as increased unbound fraction risks underdosing and rejection in donor-specific antibody-positive kidney transplant recipients. The aim of this study was to investigate the interaction between IVIG-induced IgG elevation and TAC during preoperative desensitization. Methods: This retrospective study compared TAC trough levels (C 0 ), area under the concentration–time curve from 0 to 24 hours (AUC 0–24 ), TAC C 0 /dose (C 0 /D), TAC AUC 0–24 /dose (AUC 0–24 /D), and serum IgG levels predesensitization and postdesensitization among 3 groups: IVIG [high-dose IVIG plus plasmapheresis (PP), n = 12], PP only (n = 7), and control (n = 68). Results: Following IVIG, median whole blood TAC C 0 rose from 6.5 to 9.3 ng/mL and AUC 0–24 from 238.2 to 325.8 ng·hours/mL. Accordingly, serum IgG levels increased from 968 (898–1396) to 2647 (2349–2927) mg/dL. A linear mixed model confirmed that an increase in serum IgG levels was independently associated with an elevated TAC AUC 0–24 /D. This apparent TAC AUC 0–24 /D increase peaked at 1.3-fold and persisted for 2 weeks; however, no clinical evidence of TAC toxicity (eg, hyperkalemia) was observed, suggesting an unlikely rise in the unbound concentration. Conclusions: IVIG induced an apparent elevation in whole-blood TAC concentrations, mediated by elevated serum IgG levels. Because this elevation theoretically may not reflect an increase in the unbound fraction, empirical dose reductions based solely on whole-blood levels risk compromising immunosuppression. A vigilant therapeutic drug monitoring strategy is essential to account for the protein-binding interaction and potentially optimize immunosuppression in high-risk patients.
- 23 October 2025
- Published by S. Karger AG in Nephron
- Vol. 149 (Suppl. 1) , 60-69
Transcriptomic Insights into Polyomavirus Nephropathy in Kidney Transplants: Evaluating the Utility of the Banff Human Organ Transplant Panel
Background: Polyomavirus nephropathy (PyVN) is a significant complication following kidney transplantation, characterized by tubulointerstitial inflammation that mimics T-cell-mediated rejection (TCMR). The Banff Human Organ Transplant (B-HOT) panel, a transcriptomic analysis tool comprising 770 genes, has been developed to facilitate the diagnosis of allograft rejection. However, its utility in distinguishing PyVN from TCMR remains unclear. Objective: This study aimed to evaluate the biochemical characteristics of PyVN and TCMR using the B-HOT panel, investigate changes after PyVN treatment, and assess the panel’s diagnostic utility. Methods: Formalin-fixed paraffin-embedded tissue samples from 11 PyVN patients were analyzed both at diagnosis and follow-up using the B-HOT panel. Public datasets were compared to identify differentially expressed genes and activated pathways. Prognostic factors were explored based on viral clearance and renal function outcomes. Results: BK VP1 gene expression was significantly elevated in PyVN cases, aiding diagnosis. While tissue homeostasis pathways were upregulated in PyVN compared to TCMR in the original data, no specific pathways were identified in public datasets. Successful viral clearance correlated with enhanced T-cell checkpoint signaling at diagnosis, suggesting its role in immune-mediated viral elimination. Conclusion: The B-HOT panel provides limited utility for diagnosing PyVN beyond viral gene quantification. However, T-cell checkpoint signaling may serve as a prognostic marker for viral clearance and renal function preservation in PyVN cases. Further studies are needed to refine molecular diagnostics for PyVN and improve transplant outcomes.
- 23 October 2025
- Published by S. Karger AG in Nephron
- Vol. 149 (Suppl. 1) , 60-69
Transcriptomic Insights into Polyomavirus Nephropathy in Kidney Transplants: Evaluating the Utility of the Banff Human Organ Transplant Panel
Background: Polyomavirus nephropathy (PyVN) is a significant complication following kidney transplantation, characterized by tubulointerstitial inflammation that mimics T-cell-mediated rejection (TCMR). The Banff Human Organ Transplant (B-HOT) panel, a transcriptomic analysis tool comprising 770 genes, has been developed to facilitate the diagnosis of allograft rejection. However, its utility in distinguishing PyVN from TCMR remains unclear. Objective: This study aimed to evaluate the biochemical characteristics of PyVN and TCMR using the B-HOT panel, investigate changes after PyVN treatment, and assess the panel’s diagnostic utility. Methods: Formalin-fixed paraffin-embedded tissue samples from 11 PyVN patients were analyzed both at diagnosis and follow-up using the B-HOT panel. Public datasets were compared to identify differentially expressed genes and activated pathways. Prognostic factors were explored based on viral clearance and renal function outcomes. Results: BK VP1 gene expression was significantly elevated in PyVN cases, aiding diagnosis. While tissue homeostasis pathways were upregulated in PyVN compared to TCMR in the original data, no specific pathways were identified in public datasets. Successful viral clearance correlated with enhanced T-cell checkpoint signaling at diagnosis, suggesting its role in immune-mediated viral elimination. Conclusion: The B-HOT panel provides limited utility for diagnosing PyVN beyond viral gene quantification. However, T-cell checkpoint signaling may serve as a prognostic marker for viral clearance and renal function preservation in PyVN cases. Further studies are needed to refine molecular diagnostics for PyVN and improve transplant outcomes.
- 11 September 2025
- Published by S. Karger AG in Nephron
- Vol. 149 (Suppl. 1) , 14-21
Clinicopathological Analysis of Immunologically High-Risk Kidney Transplantation Using High-Dose Intravenous Immunoglobulin as Desensitization Therapy
Introduction: High-dose intravenous immunoglobulin (H-IVIg) has been used as a desensitization therapy for donor-specific anti-HLA antibody (DSA)-positive kidney transplant recipients in Japan since 2019. This study reports the clinical and pathological outcomes of patients who received H-IVIg at Sapporo City General Hospital. Methods: This study included 7 patients who underwent kidney transplantation at our hospital and received H-IVIg as pretransplant desensitization therapy. At our institution, H-IVIg is indicated for patients with a history of sensitization, such as prior blood transfusion, pregnancy, or organ transplantation, and who tested positive in a flow cytometry crossmatch (FCXM) before transplantation. The recipients (mean age: 55.2 ± 11 years) included one male and six females. The donors (mean age: 62.8 ± 8.8 years) included five males and two females. All were living donor transplants, with four cases involving spousal donation. We assessed the immunological status before and after desensitization and retrospectively analyzed kidney function, anti-donor antibody status, and pathological findings. Results: Before desensitization, 6 patients were FCXM-T positive, and all were FCXM-B positive. After desensitization, 3 patients converted to FCXM-T negative; however, all remained FCXM-B positive. The Luminex single antigen test was positive in 4 patients before desensitization; one converted to negative, while one initially negative patient became positive. Consequently, 4 patients remained DSA positive at transplantation. Three patients experienced acute rejection within 1 month: one had antibody-mediated rejection (ABMR), and two had T-cell-mediated rejection. All patients responded to antirejection therapy, preserving their graft function. At 36 months of follow-up, all the patients survived with functional grafts. Pathological findings revealed early rejection in 3 patients, who later developed chronic ABMR. The remaining 4 patients did not experience rejection episodes. Conclusion: The H-IVIg regimen facilitates kidney transplantation in immunologically high-risk recipients. However, the risk of early postoperative rejection and the potential development of chronic ABMR necessitate careful posttransplant monitoring.
- 11 September 2025
- Published by S. Karger AG in Nephron
- Vol. 149 (Suppl. 1) , 14-21
Clinicopathological Analysis of Immunologically High-Risk Kidney Transplantation Using High-Dose Intravenous Immunoglobulin as Desensitization Therapy
Introduction: High-dose intravenous immunoglobulin (H-IVIg) has been used as a desensitization therapy for donor-specific anti-HLA antibody (DSA)-positive kidney transplant recipients in Japan since 2019. This study reports the clinical and pathological outcomes of patients who received H-IVIg at Sapporo City General Hospital. Methods: This study included 7 patients who underwent kidney transplantation at our hospital and received H-IVIg as pretransplant desensitization therapy. At our institution, H-IVIg is indicated for patients with a history of sensitization, such as prior blood transfusion, pregnancy, or organ transplantation, and who tested positive in a flow cytometry crossmatch (FCXM) before transplantation. The recipients (mean age: 55.2 ± 11 years) included one male and six females. The donors (mean age: 62.8 ± 8.8 years) included five males and two females. All were living donor transplants, with four cases involving spousal donation. We assessed the immunological status before and after desensitization and retrospectively analyzed kidney function, anti-donor antibody status, and pathological findings. Results: Before desensitization, 6 patients were FCXM-T positive, and all were FCXM-B positive. After desensitization, 3 patients converted to FCXM-T negative; however, all remained FCXM-B positive. The Luminex single antigen test was positive in 4 patients before desensitization; one converted to negative, while one initially negative patient became positive. Consequently, 4 patients remained DSA positive at transplantation. Three patients experienced acute rejection within 1 month: one had antibody-mediated rejection (ABMR), and two had T-cell-mediated rejection. All patients responded to antirejection therapy, preserving their graft function. At 36 months of follow-up, all the patients survived with functional grafts. Pathological findings revealed early rejection in 3 patients, who later developed chronic ABMR. The remaining 4 patients did not experience rejection episodes. Conclusion: The H-IVIg regimen facilitates kidney transplantation in immunologically high-risk recipients. However, the risk of early postoperative rejection and the potential development of chronic ABMR necessitate careful posttransplant monitoring.
- Open Access
- 1 June 2025
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 3 (6)
Kidney Transplantation in a Patient With Bilateral Renal Tumor Associated With Solitary Birt-Hogg-Dube Syndrome: A Case Report
Background: Birt-Hogg-Dube syndrome (BHD) is a rare autosomal dominant disorder characterized by skin fibrofolliculomas, pulmonary cysts, and renal tumors. Although few patients with renal tumors associated with BHD syndrome develop kidney failure, we report a case of kidney transplantation (KTx) with bilateral renal cancer associated with solitary BHD syndrome. Case Presentation: A 62-year-old man with kidney failure because of contrast-induced nephropathy presented for living donor transplantation. CT revealed renal cancer in the left kidney and multiple tumors on the contralateral side. A left nephrectomy was performed first, and hte histological diagnosis was chromophobe- and clear-cell-type renal cell carcinoma (RCC), which raised the possibility of BHD syndrome. Further examination revealed a history of multiple skin follicles on the face and small bullae in the lungs, without a family history of renal tumors or pneumothorax. The patient underwent simultaneous KTx with laparoscopic right nephrectomy because of the potential malignancy of multiple tumors, which were diagnosed as 2 RCC. Genetic testing confirmed a diagnosis of BHD syndrome. No recurrence was observed for up to one and a half years postoperatively. Conclusions: This is the second reported case of KTx in a patient with BHD syndrome and the first case of solitary BHD syndrome. Although this rare disease may have been overlooked, transplant physicians should be aware of it. Although simultaneous KTx with nephrectomy because of the suspicion of renal cancer remains unclear, this patient exemplifies a case of renal cancer associated with BHD syndrome.
- 1 June 2025
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 3 (6)
Open AccessKidney Transplantation in a Patient With Bilateral Renal Tumor Associated With Solitary Birt-Hogg-Dube Syndrome: A Case Report
Background: Birt-Hogg-Dube syndrome (BHD) is a rare autosomal dominant disorder characterized by skin fibrofolliculomas, pulmonary cysts, and renal tumors. Although few patients with renal tumors associated with BHD syndrome develop kidney failure, we report a case of kidney transplantation (KTx) with bilateral renal cancer associated with solitary BHD syndrome. Case Presentation: A 62-year-old man with kidney failure because of contrast-induced nephropathy presented for living donor transplantation. CT revealed renal cancer in the left kidney and multiple tumors on the contralateral side. A left nephrectomy was performed first, and hte histological diagnosis was chromophobe- and clear-cell-type renal cell carcinoma (RCC), which raised the possibility of BHD syndrome. Further examination revealed a history of multiple skin follicles on the face and small bullae in the lungs, without a family history of renal tumors or pneumothorax. The patient underwent simultaneous KTx with laparoscopic right nephrectomy because of the potential malignancy of multiple tumors, which were diagnosed as 2 RCC. Genetic testing confirmed a diagnosis of BHD syndrome. No recurrence was observed for up to one and a half years postoperatively. Conclusions: This is the second reported case of KTx in a patient with BHD syndrome and the first case of solitary BHD syndrome. Although this rare disease may have been overlooked, transplant physicians should be aware of it. Although simultaneous KTx with nephrectomy because of the suspicion of renal cancer remains unclear, this patient exemplifies a case of renal cancer associated with BHD syndrome.
- 17 November 2023
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15196
Kidney donor age of 50 years or above is a risk factor for calcineurin inhibitor‐induced nephrotoxicity
Introduction: Calcineurin inhibitor (CNI)‐induced nephrotoxicity (CNI‐T) is a post‐transplantation complication that leads to graft dysfunction. Older‐donor kidney grafts may be susceptible to chronic CNI exposure because of long‐term arteriolar damage. The primary aim of this study was to examine the CNI‐T incidence and time‐course changes in the graft function according to donor age.Methods: We included 334 kidney transplant recipients. CNI‐T was defined by Banff arteriolar hyaline thickening scores of ≥2 based on allograft protocol biopsy. Depending on donor age, participants were divided into the D > 70 (≥70 years), D60 (60–69 years), D50 (50–59 years), and D < 49: (≤49 years) groups. We investigated the extent to which CNI‐T affected the transplanted kidney function. Patients who did not develop CNI‐T during the study period were included in the non‐CNI‐T group; the remaining were grouped into the CNI‐T group.Results: The CNI‐T incidence was higher in donors aged >50 years. Compared to D < 49, the CNI‐T risk was 1.86 times higher in D50 and 2.9 times higher in D > 70. Furthermore, the CNI‐T group exhibited a significantly lower graft function 10 years after transplantation.Conclusion: CNI‐T incidence increases in donors aged ≥50 years and affects renal function after 10 years.
- 17 November 2023
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15196
Kidney donor age of 50 years or above is a risk factor for calcineurin inhibitor‐induced nephrotoxicity
Introduction: Calcineurin inhibitor (CNI)‐induced nephrotoxicity (CNI‐T) is a post‐transplantation complication that leads to graft dysfunction. Older‐donor kidney grafts may be susceptible to chronic CNI exposure because of long‐term arteriolar damage. The primary aim of this study was to examine the CNI‐T incidence and time‐course changes in the graft function according to donor age.Methods: We included 334 kidney transplant recipients. CNI‐T was defined by Banff arteriolar hyaline thickening scores of ≥2 based on allograft protocol biopsy. Depending on donor age, participants were divided into the D > 70 (≥70 years), D60 (60–69 years), D50 (50–59 years), and D < 49: (≤49 years) groups. We investigated the extent to which CNI‐T affected the transplanted kidney function. Patients who did not develop CNI‐T during the study period were included in the non‐CNI‐T group; the remaining were grouped into the CNI‐T group.Results: The CNI‐T incidence was higher in donors aged >50 years. Compared to D < 49, the CNI‐T risk was 1.86 times higher in D50 and 2.9 times higher in D > 70. Furthermore, the CNI‐T group exhibited a significantly lower graft function 10 years after transplantation.Conclusion: CNI‐T incidence increases in donors aged ≥50 years and affects renal function after 10 years.
- Open Access
- 11 October 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (10) , e0287059
Low dose tacrolimus exposure and early steroid withdrawal with strict body weight control can improve post kidney transplant glucose tolerance in Japanese patients
The development of diabetes mellitus (DM) after living donor kidney transplantation (KT) is a risk factor for worsening transplant kidney function, cardiac disease, and cerebrovascular disease, which may affect prognosis after KT. At our institution, all patients’ glucose tolerance is evaluated perioperatively by oral glucose tolerance tests (OGTTs) at pre-KT, and 3, 6, and 12 month (mo.) after KT. We analyzed the insulinogenic index (ISI) and homeostasis model assessment beta cell (HOMA-β) based on the immunoreactive insulin (IRI) levels to determine how glucose tolerance changed after KT in 214 patients who had not been diagnosed with DM before KT. In addition, we analyzed the body mass index (BMI) which may also influence glucose tolerance after KT. The concentration of tacrolimus (TAC) in blood was also measured as the area under the curve (AUC) to examine its effects at each sampling point. The preoperative-OGTTs showed that DM was newly diagnosed in 22 of 214 patients (10.3%) who had not been given a diagnosis of DM by the pre-KT fasting blood sugar (FBS) tests. The glucose tolerance was improved in 15 of 22 DM patients at 12 mo. after KT. ISI and IRI deteriorated only at 3 mo. after KT but improved over time. There was a trend of an inverse correlation between HOMA-β and TAC-AUC. We also found inverse correlations between IRI and an increase in BMI from 3 to 12 mo. after KT. Early corticosteroid withdrawal or the steroid minimization protocol with tacrolimus to maintain a low level of diabetogenic tacrolimus and BMI decrease after KT used by our hospital individualizes lifestyle interventions for each patient might contribute to an improvement in post-KT glucose tolerance.
- 11 October 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (10) , e0287059
Open AccessLow dose tacrolimus exposure and early steroid withdrawal with strict body weight control can improve post kidney transplant glucose tolerance in Japanese patients
The development of diabetes mellitus (DM) after living donor kidney transplantation (KT) is a risk factor for worsening transplant kidney function, cardiac disease, and cerebrovascular disease, which may affect prognosis after KT. At our institution, all patients’ glucose tolerance is evaluated perioperatively by oral glucose tolerance tests (OGTTs) at pre-KT, and 3, 6, and 12 month (mo.) after KT. We analyzed the insulinogenic index (ISI) and homeostasis model assessment beta cell (HOMA-β) based on the immunoreactive insulin (IRI) levels to determine how glucose tolerance changed after KT in 214 patients who had not been diagnosed with DM before KT. In addition, we analyzed the body mass index (BMI) which may also influence glucose tolerance after KT. The concentration of tacrolimus (TAC) in blood was also measured as the area under the curve (AUC) to examine its effects at each sampling point. The preoperative-OGTTs showed that DM was newly diagnosed in 22 of 214 patients (10.3%) who had not been given a diagnosis of DM by the pre-KT fasting blood sugar (FBS) tests. The glucose tolerance was improved in 15 of 22 DM patients at 12 mo. after KT. ISI and IRI deteriorated only at 3 mo. after KT but improved over time. There was a trend of an inverse correlation between HOMA-β and TAC-AUC. We also found inverse correlations between IRI and an increase in BMI from 3 to 12 mo. after KT. Early corticosteroid withdrawal or the steroid minimization protocol with tacrolimus to maintain a low level of diabetogenic tacrolimus and BMI decrease after KT used by our hospital individualizes lifestyle interventions for each patient might contribute to an improvement in post-KT glucose tolerance.
- Open Access
- 14 September 2023
- Published by Wiley in IJU Case Reports
- Vol. 6 (6) , 428-432
Orthotopic kidney transplantation from a living renal donor after interventional therapy for bilateral arteriosclerosis obliterans of the iliac arteries: A case report and literature review
IntroductionOrthotopic kidney transplantation is an option when heterotopic kidney transplantation into the iliac fossa is inappropriate. We report a case of orthotopic kidney transplantation following stenting of both external iliac arteries to treat arteriosclerosis obliterans.Case presentationA 56-year-old woman on hemodialysis for end-stage kidney disease underwent living-donor kidney transplantation. Desensitization therapy was administered because of her history of sensitization by pregnancy. Stents had been placed previously in both external iliac arteries. The left kidney was removed via an oblique lumbar incision. The two graft arteries were conjoined and anastomosed to the native renal artery end-to-end. The urinary tract was reconstructed by uretero-ureterostomy with ureteral stent placement. Renal function improved promptly after surgery.ConclusionPreoperative imaging of vascular anatomy is important for successful orthotopic kidney transplantation in patients who have previously undergone stenting of both external iliac arteries for arteriosclerosis obliterans.
- 14 September 2023
- Published by Wiley in IJU Case Reports
- Vol. 6 (6) , 428-432
Open AccessOrthotopic kidney transplantation from a living renal donor after interventional therapy for bilateral arteriosclerosis obliterans of the iliac arteries: A case report and literature review
IntroductionOrthotopic kidney transplantation is an option when heterotopic kidney transplantation into the iliac fossa is inappropriate. We report a case of orthotopic kidney transplantation following stenting of both external iliac arteries to treat arteriosclerosis obliterans.Case presentationA 56-year-old woman on hemodialysis for end-stage kidney disease underwent living-donor kidney transplantation. Desensitization therapy was administered because of her history of sensitization by pregnancy. Stents had been placed previously in both external iliac arteries. The left kidney was removed via an oblique lumbar incision. The two graft arteries were conjoined and anastomosed to the native renal artery end-to-end. The urinary tract was reconstructed by uretero-ureterostomy with ureteral stent placement. Renal function improved promptly after surgery.ConclusionPreoperative imaging of vascular anatomy is important for successful orthotopic kidney transplantation in patients who have previously undergone stenting of both external iliac arteries for arteriosclerosis obliterans.
- Open Access
- 2 August 2023
- Published by S. Karger AG in Nephron
- Vol. 147 (Suppl. 1) , 53-60
BK Polyomavirus-Associated Urothelial Carcinoma of the Bladder with a Background of BK Polyomavirus Nephropathy in a Kidney Transplant Recipient
Renal transplant recipients are at increased risk for the development of a malignant neoplasm. Polyomavirus-associated urothelial carcinoma is a rare tumor that occurs in renal transplant recipients, with approximately 41 cases reported since 2002. It accounts for 27–31% of all post-transplant urothelial carcinomas and develops at an average of 8.5 years after transplantation. Histologically, it shows high-grade urothelial carcinoma (95.1%) with a high frequency of glandular differentiation and micropapillary structures (58.5%) and positive immunohistochemistry for polyomavirus large T antigen, p53 (92.9%), and p16 (100%). We encountered a case of BK polyomavirus (BKPyV)-associated urothelial carcinoma of the bladder diagnosed 54 months after kidney transplantation. Histologically, it was a high-grade urothelial carcinoma with micropapillary features, and immunohistochemically, it was diffusely positive for polyomavirus large T antigen, p16, and p53. BKPyV DNA and mRNA for BKPyV large T antigen have been identified in tissues using real-time polymerase chain reaction. The same sequence of the BKPyV VP1 genome hypervariable region was detected in both transplanted kidney tissue with polyomavirus nephropathy and urothelial carcinoma tissue, suggesting that polyomavirus-associated urothelial carcinoma developed in a background of persistent polyomavirus nephropathy. This case showed typical histological features and was detected and treated at an earlier stage than has been reported. It is important to keep in mind that polyomavirus-associated urothelial carcinoma can develop early after transplantation and might be associated with polyomavirus nephropathy. Because of its rapidly progressive nature, careful follow-up with urine cytology and cystoscopy is necessary. We report this case with a literature review.
- 2 August 2023
- Published by S. Karger AG in Nephron
- Vol. 147 (Suppl. 1) , 53-60
Open AccessBK Polyomavirus-Associated Urothelial Carcinoma of the Bladder with a Background of BK Polyomavirus Nephropathy in a Kidney Transplant Recipient
Renal transplant recipients are at increased risk for the development of a malignant neoplasm. Polyomavirus-associated urothelial carcinoma is a rare tumor that occurs in renal transplant recipients, with approximately 41 cases reported since 2002. It accounts for 27–31% of all post-transplant urothelial carcinomas and develops at an average of 8.5 years after transplantation. Histologically, it shows high-grade urothelial carcinoma (95.1%) with a high frequency of glandular differentiation and micropapillary structures (58.5%) and positive immunohistochemistry for polyomavirus large T antigen, p53 (92.9%), and p16 (100%). We encountered a case of BK polyomavirus (BKPyV)-associated urothelial carcinoma of the bladder diagnosed 54 months after kidney transplantation. Histologically, it was a high-grade urothelial carcinoma with micropapillary features, and immunohistochemically, it was diffusely positive for polyomavirus large T antigen, p16, and p53. BKPyV DNA and mRNA for BKPyV large T antigen have been identified in tissues using real-time polymerase chain reaction. The same sequence of the BKPyV VP1 genome hypervariable region was detected in both transplanted kidney tissue with polyomavirus nephropathy and urothelial carcinoma tissue, suggesting that polyomavirus-associated urothelial carcinoma developed in a background of persistent polyomavirus nephropathy. This case showed typical histological features and was detected and treated at an earlier stage than has been reported. It is important to keep in mind that polyomavirus-associated urothelial carcinoma can develop early after transplantation and might be associated with polyomavirus nephropathy. Because of its rapidly progressive nature, careful follow-up with urine cytology and cystoscopy is necessary. We report this case with a literature review.
- 12 June 2023
- Published by Wiley in International Journal of Urology
- Vol. 30 (8) , 624-633
Mechanism and treatment for chronic antibody‐mediated rejection in kidney transplant recipients
Chronic antibody‐mediated rejection of kidney transplantation is a major cause of late‐stage graft loss. Donor‐specific antibodies are the main cause of antibody‐mediated rejection; in particular, de novo donor‐specific antibodies are a risk factor for chronic active antibody‐mediated rejection. The level of de novo donor‐specific antibodies tends to increase with time throughout long‐term graft survival. Donor‐specific antibodies induce humoral rejection through complement activation, which results in tissue injury and coagulation. Additionally, complement activation promotes the migration of inflammatory cells through the innate immune response, causing endothelial injury. This inflammatory response may cause persistent glomerulitis and peritubular capillaritis, leading to fixed pathological lesions that impair graft function. No treatment has been established for chronic antibody‐mediated rejection, a condition in which antibody‐mediated rejection becomes irreversible. Thus, antibody‐mediated rejection must be detected and treated while it is still reversible. In this review, we discuss the development of de novo donor‐specific antibodies and the mechanisms leading to chronic antibody‐mediated rejection and summarize the current treatment options and the latest biomarkers for detecting chronic antibody‐mediated rejection at an earlier stage.
- 12 June 2023
- Published by Wiley in International Journal of Urology
- Vol. 30 (8) , 624-633
Mechanism and treatment for chronic antibody‐mediated rejection in kidney transplant recipients
Chronic antibody‐mediated rejection of kidney transplantation is a major cause of late‐stage graft loss. Donor‐specific antibodies are the main cause of antibody‐mediated rejection; in particular, de novo donor‐specific antibodies are a risk factor for chronic active antibody‐mediated rejection. The level of de novo donor‐specific antibodies tends to increase with time throughout long‐term graft survival. Donor‐specific antibodies induce humoral rejection through complement activation, which results in tissue injury and coagulation. Additionally, complement activation promotes the migration of inflammatory cells through the innate immune response, causing endothelial injury. This inflammatory response may cause persistent glomerulitis and peritubular capillaritis, leading to fixed pathological lesions that impair graft function. No treatment has been established for chronic antibody‐mediated rejection, a condition in which antibody‐mediated rejection becomes irreversible. Thus, antibody‐mediated rejection must be detected and treated while it is still reversible. In this review, we discuss the development of de novo donor‐specific antibodies and the mechanisms leading to chronic antibody‐mediated rejection and summarize the current treatment options and the latest biomarkers for detecting chronic antibody‐mediated rejection at an earlier stage.